Mgc Pharmaceuticals Share Discussion Threads

[sloppyjoe2] 17/8/2023 16:26

What makes you think that?

[the imperialist] 17/8/2023 14:13

I'm in. My trade has been split. This has to be the bottom IMHO. Give it a week or two and we should be at the races.

[heatseek77] 14/8/2023 08:37

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant derived medicines, is pleased to announce positive pre-clinical trial results from the recently completed Pre-clinical Chronic Toxicology Evaluation of 14 days oral dose of CimetrA(R).

The recently completed study was undertaken on 32 domestic swine, that received a study treatment (three dosages groups of CimetrA(R) and Placebo) for 14 days. During this period, the clinical parameters were recorded, blood (hematology, coagulation and chemistry) and urine tests were collected and sent to the histopathological evaluation.

The study demonstrated that following the full chronic safety and toxicology analysis of CimetrA(R) in large animals - the drug was found to be safe. The histopathological analysis of the full organs spectrum demonstrated all tissues of all animals were normal and unaffected. It was concluded that the test article at the dosage administered did not induce toxicological changes. No changes in the blood and urine samples were reported.

The study was performed under animal EC approval in the GLP certified Lab Science in Action, Ness Ziona, Israel, and is an important step in the Investigational New Drug ("IND") submission preparation for the US Food and Drug Administration ("FDA"). The study was designed and managed according to industry guidelines and the IND submission is planned for Q1 2024.

Roby Zomer, CEO and Managing Director of MGC Pharmaceuticals, commented: "We are delighted with the positive clinical trial results for CimetrA(R) which paves the way for our IND submission to the FDA next year. The potential addressable market for our anti-inflammatory and immunomodulating product is considerable and this represents a key milestone for the business

[heatseek77] 14/8/2023 07:21

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant derived medicines, is pleased to announce positive pre-clinical trial results from the recently completed Pre-clinical Chronic Toxicology Evaluation of 14 days oral dose of CimetrA(R).

The recently completed study was undertaken on 32 domestic swine, that received a study treatment (three dosages groups of CimetrA(R) and Placebo) for 14 days. During this period, the clinical parameters were recorded, blood (hematology, coagulation and chemistry) and urine tests were collected and sent to the histopathological evaluation.

The study demonstrated that following the full chronic safety and toxicology analysis of CimetrA(R) in large animals - the drug was found to be safe. The histopathological analysis of the full organs spectrum demonstrated all tissues of all animals were normal and unaffected. It was concluded that the test article at the dosage administered did not induce toxicological changes. No changes in the blood and urine samples were reported.

The study was performed under animal EC approval in the GLP certified Lab Science in Action, Ness Ziona, Israel, and is an important step in the Investigational New Drug ("IND") submission preparation for the US Food and Drug Administration ("FDA"). The study was designed and managed according to industry guidelines and the IND submission is planned for Q1 2024.

Roby Zomer, CEO and Managing Director of MGC Pharmaceuticals, commented: "We are delighted with the positive clinical trial results for CimetrA(R) which paves the way for our IND submission to the FDA next year. The potential addressable market for our anti-inflammatory and immunomodulating product is considerable and this represents a key milestone for the business

[the mugger] 03/8/2023 20:50

PONZI

PLACING SHARES AT A DISCOUNT AND APPARENTLY USING THE PROCEED TO BUY SHARES ON THE OPEN MARKET.

HAHAHAHA

SCAM SCAM

[the mugger] 03/8/2023 12:09

So 50% dilution?

Whilst the Company intends to raise $2,685,728 under the SPP, MGC reserves the right to scale back applications under the SPP.

[the mugger] 03/8/2023 12:07

Whilst the Company intends to raise $2,685,728 under the SPP, MGC reserves the right to scale back applications under the SPP.

[looneytune] 31/7/2023 07:03

More Progress:-
MGC Pharmaceuticals Limited Permission for first import of Psilocybin
Intraday Mgc Pharmaceuticals Chart
Intraday Mgc Pharmaceuticals Chart
31/07/2023 7:00am
UK Regulatory (RNS & others)

TIDMMXC

RNS Number : 6410H

MGC Pharmaceuticals Limited

31 July 2023

MGC Pharma receives permission for first import of Psilocybin

31 July 2023

ASX Code: MXC

LSE Code: MXC

Highlights :


-- First importation approval of Psilocybin Raw Mushrooms to MGC Slovenian Research
-- MGC will perform an analysis on the materials with a view to further developing analytical and stability methods on the Psilocybin mushrooms.

MGC Pharmaceuticals Ltd ('MGC Pharma' or 'the Company') a European based pharmaceutical company specialising in the production and development of plant derived medicines, is pleased to announce it has been granted its first import permit for 200g of Psilocybin Raw Mushroom material to its Slovenian research facility from Psyence Group Inc's ('Psyence') Southern Africa production site as part of the material transfer agreement signed between the two companies.

Under the agreement, MGC Pharma will perform an analysis on the materials with a view to assist Psyence in the development of new psilocybin products to take to market, through its GMP-certified research facility in Slovenia that was recently approved for psilocybin compounding [1] .

Psyence is a life science biotechnology company listed on the Canadian Securities Exchange (CSE:PSYG) and quoted on the OTCQB (OTCQB:PSYGF), with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences. Psyence operates out of one of the world's first federally licensed commercial psilocybin mushroom cultivation and production facilities in Southern Africa and works to develop advanced natural psilocybin products for clinical research and development.

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of fungi. Psyence focuses on developing propriety natural psilocybin drug development and treatment protocols with a focus on palliative care. The company cultivates natural psilocybin mushrooms (Psilocybe Cubensis) at its federally licensed facility.

Following MGC's successful audit of the Psyence production site to ensure that it meets the standards necessary to proceed with the export to MGC's European facilities, MGC has submitted and was granted the import approval of psilocybin. Psyence will complete the export on receipt of the export permit. Based on the analytical findings and results of the technical evaluation of the first delivery of 200g of Psilocybin Raw Mushrooms, MGC will develop analytical methods and stability testing to meet ICH guidelines.

Roby Zomer, CEO and Managing Director of MGC Pharmaceuticals, commented: "We are delighted to receive the first import approval of psilocybin under our collaboration with Psyence, which constitutes our first entry into the psilocybin market. This partnership marks a significant milestone for MGC Pharma following our recent approval for psilocybin research in our Slovenian facility and reinforces our commitment to growth and innovation.

"By joining forces with Psyence, we are combining our respective strengths and expertise to unlock new opportunities and deliver exceptional value to our customers. This collaboration enhances our ambitions to be one of the first companies to provide Psilocybin treatments alongside our plant-based treatments."

Tony Budden, Director of Strategy and Head of Production at Psyence added: " Psyence Production is pleased to collaborate with MGC Pharma in the research and development of standardized psilocybin containing products from our mushrooms. Having access to MGC's EU-GMP R&D lab, expert team and resources will help accelerate this process and we look forward to working together."

-Ends-

Authorised for release by the board of directors, for further information please contact:

[hawkman_forever] 28/7/2023 20:15

They are leaving, as working capital is needed. Administration by the end of August.

Their scamming has come to an end.

[kenbos] 28/7/2023 12:53

Why do you think this is a positive update ? I'm not so sure

[come on] 28/7/2023 08:11

A positive update, price needs to mover forward too

[flc] 20/7/2023 13:33

Roll up, roll up...get 1m shares for just £1,300 :-)

[flc] 18/7/2023 20:41

Roll up, roll up...get 1m shares for just £1,500...back in tomorrow.

[kenbos] 18/7/2023 15:38

Have to agree whiskey my worst punt by a long way just glad it wasn't a big punt

[moonshine3] 17/7/2023 09:57

double post